Kiniksa Pharmaceuticals International (KNSA) reported Tuesday a Q2 net income and sales above market expectations.

Separately, Wedbush said in a report the firm is benefiting from continued momentum for Arcalyst, its treatment for recurrent pericarditis, a condition in which the sac around the heart becomes inflamed in repeated episodes.

Shares surged 23% as intraday trading volume grew to over 1.9 million from a daily average of about 734,000.

IQVIA (IQV) reported a year-over-year increase in Q2 adjusted earnings and revenue, and raised its 2026 outlook.

Shares jumped 12%, with intraday trading volume rising to more than 3.3 million from a daily average of about 1.6 million.

Incyte (INCY) on Tuesday reported Q2 non-GAAP earnings and sales above market expectations, and raised net sales guidance for 2026.

Shares climbed up 8% amid a surge in intraday trading volume to over 3.3 million from a daily average of about 1.7 million.

Price: 78.52, Change: +14.98, Percent Change: +23.58